Malaria booster vaccine, R21 shows continued high efficacy in children, meeting WHO-specified 75% efficacy goal
Researchers from the University of Oxford’s Jenner Institute have today reported promising new findings from their Phase 2b trials following a booster dose of the R21/Matrix-M™ malaria vaccine - which was previously demonstrated to be 77% effective in young children.
The Institute found that a vaccine booster dose at one year, following a primary three-dose regime, maintained high efficacy against malaria and continued to meet the World Health Organization’s Malaria Vaccine Technology Roadmap goal of a vaccine with at least 75% efficacy.
However, malaria is too complex a disease for any one tool to defeat on its own, and there is no silver bullet. To get back on track in the fight against malaria, the use of vaccines will need to be balanced alongside continued investment in efforts to expand access to and optimise the use of, existing interventions. If approved, R21 will add another tool to our malaria toolbox.
British-backed science is leading the development of other lifesaving malaria interventions, including next-generation insecticide-treated nets, digital diagnostics, genetically modified mosquitoes, and cutting-edge antimalarial drugs.
To ensure that the right tools get to the right people at the right time, it is vital that the UK Government commit to long-term financing for malaria research and innovation and make an ambitious pledge at The Global Fund’s Seventh Replenishment Conference on September 19th in New York.
To cut the death rates across the three diseases by 64% and ensure that a further 20 million lives are saved by 2026, this year the Global Fund is aiming to raise a total of $18 billion - the minimum required to get the world back on track toward ending three of the world’s most deadly infectious diseases – with a call for all donors, including the UK, to step up their previous commitments by 29%.